Studies have indicated that NSCLC patients with EGFR mutations (E19del/L858R) accompanied by a higher tumor mutational burden (TMB) tend to have a less favorable prognosis when treated with EGFR-TKIs than those with low TMB [12]. This evidence concerns the gene EGFR and neoplasm.